Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Treatment options for multidrug-resistant Acinetobacter species
Jacob Gilad
,
Yehuda Carmeli
*
*
Corresponding author for this work
Internal Medicine
Tel Aviv University
Tel Aviv Sourasky Medical Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
52
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment options for multidrug-resistant Acinetobacter species'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acinetobacter
100%
Adverse Patient Outcomes
20%
Antimicrobial
40%
Bloodstream Infection
20%
Carbapenem
20%
Carbapenem Resistance
20%
Clinical Experience
20%
Colistin
20%
Combination Antimicrobial Therapy
20%
Combination Therapy
20%
Community-acquired Pneumonia
20%
Cumulative Experience
20%
Difficult-to-treat
20%
Discrete Entities
20%
Drug Administration Routes
20%
Gram-negative Infections
20%
Imipenem/cilastatin
20%
Meropenem
20%
Multidrug-resistant Acinetobacter
100%
Nosocomial Pathogens
20%
Old Drugs
20%
Post-neurosurgical Meningitis
20%
Resistant Strains
20%
Severe Infection
20%
Sulbactam
20%
Surgical Site Infection
20%
Tigecycline
20%
Treatment Options
100%
Ventilator-associated Pneumonia
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter
100%
Antiinfective Agent
33%
Antimicrobial Therapy
16%
Bloodstream Infection
16%
Carbapenem
16%
Carbapenem Derivative
16%
Cilastatin
16%
Colistimethate
16%
Combination Therapy
16%
Drug Administration
16%
Gram Negative Infection
16%
Hospital Acquired Pneumonia
16%
Imipenem
16%
Infection
100%
Infectious Agent
16%
Meningitis
16%
Meropenem
16%
Observational Study
16%
Sulbactam
16%
Surgical Infection
16%
Tigecycline
16%
Ventilator Associated Pneumonia
16%
Wound
16%